RMRafael Moleron

Rafael Moleron

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rafael Moleron has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Laryngeal Cancer Recurring in the Trachea at the Site of an Old Tracheostomy: A Rare Phenomenon Successfully Managed

    by Fergus Cooper, Rafael Moleron, Muhammad Shakeel

    A patient treated with chemoradiation for a T3 N2b M0 supraglottic squamous cell carcinoma developed regional recurrence at the site of a healed temporary tracheostomy which had been performed over 10 years prior for an unrelated illness requiring intensive care. This phenomenon has not been reported in the literature and raises the hypothesis of tissue healing post-tracheostomy altering the lymphatic drainage of the larynx. The patient was treated with further chemoradiotherapy, surgical resection of the tracheal tumor mass with new tracheostomy formation. The patient continued to be closely followed up and enjoyed a good quality of life without any signs of recurrence, until he died of pneumonia.

  • Open Access

    Impact of remoteness and rurality on the treatment and survival of patients with glioblastoma in the north of Scotland

    by Damjan Veljanoski, Raphae Barlas, Aimun A.B. Jamjoom, James Walkden, Graham Horgan, Rafael Moleron, Phyo Kyaw Myint, Anastasios Giamouriadis


  • Open Access

    The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland

    by Alekh Thapa, Anna Cowell, Adam Peters, David J Noble, Allan James, Carolynn Lamb, Derek Grose, Saurabh Vohra, Stefano Schipani, Karen Mactier, et al.

    Objectives: The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma (HNSCC) in the palliative setting, contrasting with the decision made by the National Institute for Health and Care Excellence who approved monotherapy alone in England and Wales. We aimed to provide real-world performance data for first-line pembrolizumab-containing treatments for head and neck squamous cell carcinoma (HNSCC) in the palliative setting in Scotland. Materials and Methods: We analysed the electronic records of patients who initiated pembrolizumab-containing treatment between 01/03/2020–30/09/2021. Outcomes included overall survival (OS), progression-free survival (PFS), duration of response (DOR), disease control rate (DCR). Data were compared with the KEYNOTE-048 study and clinical factors were evaluated for association with survival. Results: Our cohort included 91 patients (median follow-up 10.8 months). Patient characteristics were similar to the KEYNOTE-048 study though our cohort had a higher proportion of patients with newly diagnosed, non-metastatic disease. For patients receiving monotherapy (n=76), 12-month and 24-month OS was 45% and 27%, respectively. For patients receiving pembrolizumab-chemotherapy (n=15), 12-month OS was 60% (24-month OS had not yet been reached). Experiencing ≥1 irAE (versus no irAEs), of any grade, was associated with favourable OS and PFS for patients receiving monotherapy in both univariable log-rank analysis (median OS 17.4 months versus 8.6 months, respectively, P=0.0033; median PFS 10.9 months versus 3.0 months, respectively, P<0.0001) and multivariable analysis (Cox proportional hazards regression: OS HR: 0.31, P=0.0009; PFS HR: 0.17, P<0.0001). Conclusion: Our real-world data support the KEYNOTE-048 study findings and the value of combination treatment options. Additionally, our data show irAEs of any grade, as reported in routine clinical records, are associated with better outcomes in this patient group, adding to the growing body of evidence showing irAEs are generally a positive marker of PD-L1 inhibitor response.

  • Open Access

    Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma

    by Laura Feeney, Yatin Jain, Matthew Beasley, Oliver Donnelly, Anthony Kong, Rafael Moleron, Chandran Nallathambi, Martin Rolles, Paul Sanghera, Aung Tin, et al.

    Adenoid cystic carcinoma (ACC) is a rare cancer of secretory glands. Recurrent or metastatic (R/M) ACC is generally considered resistant to cytotoxic chemotherapy. Recent phase II studies have reported improved objective response rates (ORR) with the use of the multi-kinase inhibitor lenvatinib. We sought to evaluate real-world experience of R/M ACC patients treated with lenvatinib monotherapy within the UK National Health Service (NHS) to determine the response rates by Response Evaluation Criteria of Solid Tumour (RECIST) and clinical outcomes. Twenty-three R/M ACC patients from eleven cancer centres were included. All treatment assessments for clinical decision making related to drug therapy were undertaken at the local oncology centre. Central radiology review was performed by an independent clinical trial radiologist and blinded to the clinical decision making. In contrast to previously reported ORR of 12–15%, complete or partial response was not observed in any patients. Eleven patients (52.4%) had stable disease and 5 patients (23.8%) had progression of disease as the best overall response. The median time on treatment was 4 months and the median survival from discontinuation was 1 month. The median PFS and OS from treatment initiation were 4.5 months and 12 months respectively. Multicentre collaborative studies such as this are required to evaluate rare cancers with no recommended standard of care therapy and variable disease courses.